Colorectal Cancer: Chemotherapy Backbones and Biomarker-Guided Antibodies
Bowel cancer is where the whole oncology toolbox comes together. A fluoropyrimidine backbone, a platinum or a topoisomerase partner, and then — only if the genetics allow — a targeted antibody. This is a chapter about assembly and about ONE lab result that can switch an entire drug class on or off. Learn to read the biomarkers and the treatment writes itself.
A 61-year-old woman sits with her oncologist. Her colon cancer has spread to the liver — metastatic disease. She has read online about cetuximab, an antibody that shrinks bowel tumours, and she asks why it isn't already in her plan. The oncologist doesn't say no. He says: not yet. A tissue sample is in the lab being tested for a gene called RAS. If the tumour carries a RAS mutation, cetuximab won't just fail to help — it can make things worse. One pending result decides whether an entire class of drug is on the table or off it. That single sentence — 'let's wait for the RAS result' — is the whole logic of modern colorectal treatment.
The backbone: fluoropyrimidine plus a partner
Nearly every colorectal regimen is built on one drug. That drug is a fluoropyrimidine — either intravenous 5-fluorouracil (5-FU) given with leucovorin (folinic acid, which sharpens its effect), or its oral prodrug capecitabine, which the body converts to 5-FU. These are antimetabolites you met in the Antimetabolites chapter: they masquerade as the building blocks of DNA and jam the enzyme thymidylate synthase, starving the cancer cell of the nucleotides it needs to divide. The fluoropyrimidine is the trunk; the rest of the regimen is branches bolted onto it.
To that backbone we add one of two partners. Oxaliplatin, a platinum agent from the Alkylating/platinum chapter, crosslinks DNA and blocks replication — pair it with a fluoropyrimidine and you get FOLFOX (with IV 5-FU) or CAPOX/XELOX (with oral capecitabine). Or we add irinotecan, a topoisomerase-I inhibitor from the Anthracyclines/topoisomerase chapter, which stops the enzyme that unwinds DNA — pair it with 5-FU and you get FOLFIRI. FOLFOX and FOLFIRI are the two workhorse doublets of bowel cancer.
After surgery for a stage III colon cancer (lymph nodes involved), adjuvant chemotherapy — typically FOLFOX or CAPOX for 3–6 months — mops up micrometastases and reduces recurrence. In metastatic (stage IV) disease that can't be cured by surgery, these same doublets are given as palliative, life-prolonging therapy, and biologics are layered on top. Same drugs, different intent: cure-adjacent after surgery, control in metastatic disease.
- Every backbone contains a fluoropyrimidine: IV 5-FU/leucovorin or oral capecitabine.
- FOLFOX / CAPOX = fluoropyrimidine + oxaliplatin (platinum).
- FOLFIRI = fluoropyrimidine + irinotecan (topoisomerase-I inhibitor).
- Stage III → adjuvant chemo after surgery; stage IV → palliative doublets + biologics.
- Capecitabine is an oral prodrug converted to 5-FU — same mechanism, oral convenience.
The turning point: biomarkers decide the biologics
In metastatic disease, chemistry is only half the plan. The other half is written by the tumour's molecular profile — the domain of the Precision-oncology chapter. Before a single biologic is chosen, the tissue is tested for RAS (KRAS/NRAS) mutations, BRAF-V600E status, MSI/mismatch-repair status, and often HER2. Each result opens or closes a specific door. This is why oncologists wait: the biomarkers are not academic — they are the switchboard that determines which targeted drug helps, which does nothing, and which could harm.
Two families of biologic sit on top of chemo. The anti-VEGF antibody bevacizumab starves the tumour's blood supply by blocking vascular endothelial growth factor; it adds benefit across most patients regardless of RAS status. The anti-EGFR antibodies cetuximab and panitumumab block the epidermal growth factor receptor — but only work in a specific subgroup, which brings us to the single most important rule in this chapter. Both antibody families come from the Monoclonal-antibodies chapter; here we learn WHEN each earns its place.
The RAS rule, in one line: anti-EGFR antibodies (cetuximab, panitumumab) work ONLY in RAS wild-type tumours, and are most effective in LEFT-sided (descending/sigmoid/rectal) primaries. A RAS mutation lies downstream of EGFR — so blocking the receptor upstream is pointless; the pathway is already switched on from below. Give an anti-EGFR to a RAS-mutant tumour and you add toxicity with zero benefit, and possibly worse outcomes. Always test RAS first.
The rarer switches: BRAF, MSI-high and HER2
Beyond RAS, three less common biomarkers unlock their own targeted strategies. A BRAF-V600E mutation marks an aggressive tumour that responds poorly to chemo alone — here a BRAF-inhibitor combination (encorafenib plus cetuximab) targets the mutated pathway directly. A HER2-amplified tumour, in selected RAS wild-type cases, can respond to anti-HER2 therapy borrowed from breast/gastric cancer. Each is a small subgroup, but for the patient who has it, testing is the difference between a drug that works and one that never gets tried.
The most striking switch is MSI-high / mismatch-repair-deficient (dMMR) disease. These tumours carry a broken DNA-proofreading system, so they accumulate thousands of mutations — making them highly visible to the immune system. Here the checkpoint inhibitor pembrolizumab, an anti-PD-1 antibody from the Checkpoint-inhibitors chapter, unleashes the patient's own T-cells and produces durable, sometimes dramatic responses — outperforming chemotherapy in the first-line metastatic MSI-high setting. Miss the MSI test and you miss this option entirely.
- Anti-VEGF (bevacizumab) adds to chemo broadly, independent of RAS status.
- Anti-EGFR (cetuximab/panitumumab): RAS wild-type + left-sided only.
- BRAF-V600E mutant → encorafenib + cetuximab (BRAF-inhibitor combination).
- MSI-high / dMMR → immunotherapy (pembrolizumab) works exceptionally well.
- HER2-amplified → anti-HER2 therapy in selected RAS wild-type cases.
Knowing the backbone means knowing its toxicities
Each backbone drug carries a signature side effect you must anticipate. Oxaliplatin causes a distinctive cold-induced peripheral neuropathy — patients get pins-and-needles or throat tightness triggered by cold drinks and cold air, so they are counselled to avoid cold exposure during infusion. Irinotecan is defined by diarrhoea in two flavours: an EARLY cholinergic diarrhoea (with cramping and sweating during infusion, treated with atropine) and a LATE diarrhoea days later (treated aggressively with loperamide). Confusing the two mismanages the patient.
5-FU and capecitabine are broken down by the enzyme dihydropyrimidine dehydrogenase (DPD). A patient with inherited DPD deficiency clears the drug far too slowly, so a standard dose becomes a life-threatening overdose — severe mucositis, marrow failure, and death have occurred. This is why guidelines increasingly test DPYD (the DPD gene) before starting. The other classic fluoropyrimidine toxicity is hand-foot syndrome (palmar-plantar erythrodysesthesia) — painful red, peeling palms and soles, especially with capecitabine.
One more layer sits before treatment even begins: prevention and screening. Colorectal cancer is largely preventable, because it grows slowly from removable adenomatous polyps. Colonoscopy is the cornerstone — it finds and removes polyps before they turn malignant — and regular screening from around age 45 catches disease early, when it is curable. Long-term low-dose aspirin has a modest chemopreventive effect on colorectal cancer in selected people, though it is not prescribed for prevention alone because of bleeding risk. The best colorectal drug is often the polyp never allowed to become cancer.
- Giving an anti-EGFR antibody (cetuximab/panitumumab) in RAS-mutant disease — no benefit, added harm. Always test RAS first.
- Starting 5-FU or capecitabine without considering DPD (DPYD) deficiency — a normal dose can be fatal.
- Mismanaging irinotecan diarrhoea: EARLY cholinergic → atropine; LATE → loperamide. Don't swap them.
- Overlooking MSI / mismatch-repair testing — it is the key that unlocks immunotherapy (pembrolizumab).
A patient with left-sided metastatic colorectal cancer is found to have a KRAS mutation. Which drug is now INAPPROPRIATE to add?
- Backbone = fluoropyrimidine (5-FU/leucovorin or capecitabine) + oxaliplatin (FOLFOX/CAPOX) or irinotecan (FOLFIRI).
- Biologics are biomarker-gated: anti-EGFR only in RAS wild-type/left-sided; BRAF-V600E → encorafenib+cetuximab; MSI-high → pembrolizumab; HER2 → anti-HER2.
- Bevacizumab (anti-VEGF) adds to chemo broadly, independent of RAS.
- Signature toxicities: oxaliplatin cold neuropathy; irinotecan diarrhoea (early=atropine, late=loperamide); 5-FU DPD deficiency + hand-foot syndrome.
- NCCN Clinical Practice Guidelines in Oncology — Colon Cancer & Rectal Cancer (systemic therapy and biomarker testing).
- ESMO Clinical Practice Guidelines — Metastatic colorectal cancer: diagnosis, treatment and follow-up.
- Brunton LL, et al. Goodman & Gilman's The Pharmacological Basis of Therapeutics — Antineoplastic agents: fluoropyrimidines, platinums, topoisomerase inhibitors.
- DeVita, Hellman & Rosenberg's Cancer: Principles & Practice of Oncology — Cancer of the colon and rectum.
- Whalen K. Lippincott Illustrated Reviews: Pharmacology — Anticancer drugs and targeted therapies.
